BioBam and Biomatters announce the launch of a solution for the functional annotation and analysis of genomics datasets: Blast2GO PRO Plugin for Geneious.
July 01, 2015 02:02 PM Eastern Daylight Time
VALENCIA, Spain and AUCKLAND, New Zealand
BioBam and Biomatters are very happy to announce the release of an integrated plugin on the Geneious platform for molecular biologists to comprehensively functionally annotate and interpret novel sequences. The Blast2GO PRO plugin covers an entire workflow for the functional analysis of transcriptomic data and presents a solution for the functional annotation and interpretation of genomic datasets.
The new plugin allows out-of-the-box to assign biological functions to newly discovered unknown genes and proteins, making them readily prepared for further analysis. Dr. Stefan Götz, CEO at BioBam, states: “We are very happy to announce this plugin. The collaboration with Biomatters is a great opportunity and thanks to the Geneious Plugin Dev-Kit we could integrate Blast2GO seamlessly. Everyone interested in high-quality functional annotation of novel sequence data and the functional interpretation of genomic datasets should definitely give it a try.” Introductory pricing: The plugin is now available via the Blast2GO website and can be procured throughout July 2015 at a 30% discount. More information here: https://www.blast2go.com/b2g-plugins/geneious-plugin
BioBam, founded in 2011 and located in Valencia, Spain provides bioinformatics solutions for the functional annotation and analysis of genomic datasets to the scientific community. BioBam’s leading product, Blast2GO, counts with over 3000 scientific citations and is used by top private and public research institutions worldwide. It presents an all-in-one solution for functional genomics tasks, especially popular in non-model organism research. For further information, please visit http://www.biobam.com
Biomatters was founded in 2003 with a mission to create bioinformatics solutions for the analysis, interpretation, and application of molecular sequence data. Headquartered in New Zealand with offices in the United States and Europe, and users in more than 100 countries worldwide, Biomatters solutions enhance productivity in over 3,000 universities, research institutes and companies. For further information, please visit http://biomatters.com
- BioBam: Dr. Stefan Götz, CEO P: +34 961 059 686 E: firstname.lastname@example.org or
- Biomatters: Melissa Pentecost , Marketing and Communications Manager P: +64 9 379 5064 E: email@example.com